Direct Flow attracts $27m from Johnson & Johnson et al:
This article was originally published in Clinica
Executive Summary
Direct Flow Medical, a company developing a percutaneous heart valve replacement system, has bagged $27m in a series B financing co-led by Johnson & Johnson's investment arm and Foundation Medical Partners. Vantage Point Venture Partners and ePlanet - two new investors - also participated in the round, together with existing shareholders EDF Ventures, New Lead Venture Partners and Spray Venture Partners. Direct Flow's catheter-based system provides doctors with a minimally-invasive, transfemoral approach to replace diseased heart valve with a pericardial tissue implant. The Santa Rosa, California company initiated its European clinical study in September, following a first-in-man in Germany.